Mitochondria-derived Methylmalonic Acid is Associated with Advanced Fibrosis Risks in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): Results from the NHANES 1999–2004

Qi Huang,Li,Linjian Yang,Linong Ji,Xiantong Zou
DOI: https://doi.org/10.1016/s0168-8278(22)01255-7
IF: 25.7
2022-01-01
Journal of Hepatology
Abstract:Spearman correlation.Receiver operating characteristics (ROC) analyses were performed with cut-off selected based on Youden's Index, where FIB-4, K 1 and CTHU were combined using logistic regression.Results: Of 45 enrolled patients, 31 were female, 54 ± 13 years, and BMI 34.0 ± 5.7 kg/m 2 ; 16% of patients had inflammation >3, while 58% had NAS >4 and 29% with fibrosis ≥3.FIB-4 correlated with fibrosis significantly (r = 0.58, p < 0.001), as expected, but not with NAS (r = 0.2, p = 0.178).K 1 and CTHU showed significant correlations with NAS.As shown prior, the dual-variate model of K 1 +CTHU could detect clinical NASH but not fibrotic NASH.When FIB-4 score was combined in the model it was able to detect fibrotic NASH with an AUC of 0.781 (Figure 1) and severe fibrotic NASH with an AUC of 0.845.The triple variate model of 1.46001*K1-0.04009*CTHU+ 1.27309*FIB-4 ≥1.574408, was able to predict fibrotic NASH with a sensitivity of 83% and a specificity of 64%.While 3.27447*K1 + 0.00597*CTHU + 0.99330*FIB-4 ≥-1.296305 predicted severe fibrotic NASH with a sensitivity of 91% and specificity 68%.Conclusion: Combination of non-invasive serum and imaging tests enabled detection of clinical fibrotic NASH.Studies in larger and diverse cohorts will enable establishing this tool for determination of clinical changes in NAFLD patients.
What problem does this paper attempt to address?